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Funds awarded after peer review of
grant applications by committees
established by the National
Institutes of Health (NIH) directly
affects the careers of many
biomedical scientists. The scientific
tastes and judgments of peer review
committees also shape fields by
favoring specific questions and
approaches to particular scientific
opportunities that the committees
favor. Such a process naturally
generates a considerable amount of
discussion in the scientific
community. As someone who spent
most of his scientific career as a
review administrator at the NIH it
distresses me that these discussions
are usually based on ill-founded
anecdotes and misinformation. 
This is fueled by the
secretiveness in which the NIH
shrouds the review system in a
misguided attempt to maintain
confidentiality and is coupled with
the protective egotism by
which applicants insulate themselves
from painful criticism. I hope to
dispel some myths and
misperceptions regarding peer
review of NIH grant applications.
The scientific review
administrators (SRAs) at the NIH are
not necessarily ‘failed scientists with
personality disorders,’ an epithet
with which I was greeted when I first
came to NIH. Despite the fact that
they are often the conduits of bad
news, this is not the highlight of their
day. They are individuals promoting
the mission of the NIH and
facilitating the scientific efforts of
others. This is not always an easy
task given the arcane, almost
Byzantine, regulation and policy
constraints. Equally limiting is a
bureaucratic culture that rarely
rewards innovation. Nevertheless,
SRAs at the NIH know the grant
process thoroughly and are happy to
guide and advise applicants when
necessary. Although they see this
task as important, applicants must
seek them out. Investigators should
call NIH administrators early on
when preparing applications and
often thereafter.
Probably the most important,
and certainly the most visible,
responsibility of the SRA is
nomination of scientists to become
members of the review group.
Although the NIH Director makes
the appointment, nomination is
tantamount to appointment, as long
as the political requirements that
ensure gender equity, and geographic
and racial diversity are satisfied.
There is a tendency to see the
reviewers as nitpickers whose
strength is negativity. Nothing is
further from the truth
Although the higher echelons at the
NIH trumpet the mantra of ‘the best
and the brightest,’ my experience
does not bear this out. In over 20
years, not once was I questioned
about the scientific credentials of
nominees or my rationale for
selecting them. However, it was not
unusual for the approval of my
nominations to be held up for
months because someone (usually,
unidentified) in the chain of
command thought that too few
women, minorities or citizens of
North Dakota were included. In one
case, I had a Nobel laureate, and in
another, a Fellow of the Royal
Academy, sitting on their hands
while I haggled over the political
correctness of the nominees to a
review group.
You might question the wisdom
of placing such an important
responsibility in the hands of the
SRA. A look at study section rosters
(available via the NIH homepage) is
unlikely to settle the issue. Most
review groups have at least some
outstanding members; the noticeable
problem is that, in general, the
quality within any roster is variable
as is the quality among the various
committees. However, a few rosters
will be seen to be outstanding from
top to bottom. My judgment is that
the SRA is in the best position to
make the selections. Having been
involved in the review of
innumerable applications, (s)he
should be aware of the significant
open questions and impediments to
progress in a particular field and who
are the major players. (S)he can
consult the leading scientists in the
US. Thus, weaknesses of the rosters
are not due to the level at which the
decisions are made, but to failures in
quality control in selecting SRAs.
Some people, even those at the
highest levels at the NIH, believe
that a contributing factor is that
the best people are refusing to
serve. I can only respond that, in
22 years, only three or four people
refused service on the Cell Biology
Study Section.
The second most important role
played by the SRA is the creation of
an environment at the study section
meeting that  encourages the
reviewers to see beyond their own
experiments and biases. Creating
such an environment is difficult but
once established, it tends to be self-
perpetuating. Reviewers leave
feeling that they have spent time
fruitfully and that they have learned
as much as they taught. 
But researchers outside the study
section tend to view the meetings
more negatively. As only about a
third of the applications reviewed at
one meeting are funded, at least two
thirds of the applicants are
disappointed. There is a tendency to
see the reviewers as nitpickers
whose strength is negativity.
Nothing is further from the truth.
Reviewers sacrifice at least two
weeks of productivity in preparation
for every study section that they
attend. Like all scientists, their
passion is good and challenging
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science. They want to be excited, to
be wowed by the applications and by
the discussions that they
engender — that is their intellectual
payoff for the hard work and angst
engendered by study section service.
Reviewers do not begin by looking
for reasons to denigrate an
application; they look for substance,
for reasons to say, ‘this work must be
done — if successful it will surely
have a great impact.’ Much is said
about the conservatism of study
sections but in my experience this is
mainly a reflection of the
conservatism of applicants.
Most applications are
distressingly similar. The organisms
or systems may change but the
questions and approaches barely
differ. A novel application, well
argued, stands out like a bright
beacon and is rewarded by study
section members.
There is another important
factor that motivates study section
members to be fair. Participating
in the meeting are some of the
influential practitioners in their
field who know who is competing
and who is collaborating. These
are colleagues whose respect it is
imperative study section members
maintain. The upshot is that
reviewers give their competitors
the benefit of the doubt and
collaborators are held to a very
high standard. Few wish to look
the fool by seeming to be self-
serving or gullible.
The NIH peer review system
is not perfect, nor do I believe that it
is perfectible since it depends to
such a high degree on the
personalities and talents of people. It
is, as many have said, the best
system we have for distributing the
largesse provided by the public. It
works best when all participants
recognize that it is a human endeavor
with all the strengths and
weaknesses that that entails.
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In mitosis and meiosis, unattached
kinetochores are sources for signaling
the spindle checkpoint which
inhibits precocious sister chromatid
separation and prevents aneuploidy
(reviewed in [1]). The 3F3/2 anti-
phosphoepitope antibody recognizes
a phosphoepitope present on
unattached kinetochores that is
sensitive to mechanical tension
imparted by microtubule binding
[2–4]. Intracellular injection of this
antibody artificially preserves the
phosphoepitope at kinetochores,
even after microtubule attachment,
and delays the onset of anaphase [5].
The anaphase-promoting
complex/cyclosome (APC/C) is an
E3/ubiquitin ligase required for
anaphase onset. The activation
and/or targeting of the APC/C is
regulated by the spindle checkpoint.
Activity of the APC/C is influenced
by its phosphorylation, and by its
association with inhibitory and/or
activating proteins (reviewed in
[6–8]). Here, we show that the 3F3/2
anti-phosphoepitope antibody binds
two mitotically phosphorylated
components of the APC/C.
Extracts from mammalian cells,
arrested in S phase with
hydroxyurea or in mitosis with
microtubule inhibitors, were
immunoprecipitated with anti-
Cdc27 antibody and 3F3/2 antibody.
As previously shown, anti-Cdc27
antibody immunoprecipitates the
APC/C complex from both
interphase and mitotic cell extracts
(Figure 1a) [9]. In mitotic extracts
both Cdc27 and Cdc16 protein
exhibited reduced mobilities
(Figure 1a, lane 8). Treatment of the
mitotic APC/C with phosphatase
increased the mobilities to those of
the S-phase extract (Figure 1a,
lane 11) indicating that the reduced
mobilities of mitotic Cdc27 and
Cdc16 are likely to be due to
M-phase-specific phosphorylation.
The 3F3/2 antibody quantitatively
immunoprecipitated mitotic APC/C
proteins and immunoprecipitated
associated M-phase specific
regulatory proteins Cdc20 and Mad2
(Figure 1a (lanes 14 and 15) and b).
The 3F3/2 antibody preferentially
precipitated the reduced-mobility
(phosphorylated) forms of APC/C
components. The 3F3/2 antibody
did not immunoprecipitate the
APC/C from S-phase extract
(Figure 1a, lanes 6 and 7). Thus the
3F3/2 antibody recognizes M-phase-
specific phosphorylations on one or
more components of the APC/C. 
Western blotting of mitotic
APC/C with the 3F3/2 antibody
revealed no bands (data not shown)
suggesting that the phosphoepitope
recognized by the 3F3/2 antibody
was denatured or destroyed during
SDS–gel electrophoresis and
electroblotting. To identify
prospective targets of the 3F3/2
within the APC/C, we first
immunoprecipitated the APC/C from
mitotic cell extracts using anti-Cdc27
antibody and applied 3F3/2 antibody
that had been covalently modified by
binding the trifunctional crosslinking
reagent sulfosuccimimidyl
[2-6-(biotinamido)-2-(p-azido-
benzamido)-hexanoamido)ethyl-
1,3′dithio-proprionate (Sulfo-SBED,
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